One identified mechanism of therapy resistance in CLL involves reduced sensitivity to rituximab-induced antibody-dependent cell-mediated cytotoxicity (ADCC) due to natural killer (NK) cell production of BAFF [72]. The gene discussed is TNFSF13B; the disease is B-cell chronic lymphocytic leukemia.